300109 Stock Overview
Engages in the fine chemical and medical care businesses in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Boai NKY Medical Holdings Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.64 |
| 52 Week High | CN¥16.32 |
| 52 Week Low | CN¥8.02 |
| Beta | 0.12 |
| 11 Month Change | -6.78% |
| 3 Month Change | 8.78% |
| 1 Year Change | -4.63% |
| 33 Year Change | -17.21% |
| 5 Year Change | 27.51% |
| Change since IPO | -53.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300109 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -3.6% | -1.8% | -1.2% |
| 1Y | -4.6% | -7.8% | 3.1% |
Return vs Industry: 300109 exceeded the CN Chemicals industry which returned -7.8% over the past year.
Return vs Market: 300109 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 300109 volatility | |
|---|---|
| 300109 Average Weekly Movement | 7.9% |
| Chemicals Industry Average Movement | 7.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300109 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300109's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,165 | Junzheng Zhang | www.boai-nky.com |
Boai NKY Medical Holdings Ltd. engages in the fine chemical and medical care businesses in China and internationally. The company offers polyvinylpyrrolidone (PVP) series products, and vinyl methyl ether and maleic acid products; anhydride copolymer (PVME/MA) series products; GBL, 2-pyrrolidone, NVP monomer, PVPK series (povidone), copovidone, and other VP/VA copolymer series products; and PVPP (cross-linked povidone), PVP-I, and related pharmaceutical intermediates.
Boai NKY Medical Holdings Ltd. Fundamentals Summary
| 300109 fundamental statistics | |
|---|---|
| Market cap | CN¥6.13b |
| Earnings (TTM) | CN¥399.35m |
| Revenue (TTM) | CN¥1.49b |
15.3x
P/E Ratio4.1x
P/S RatioIs 300109 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300109 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.49b |
| Cost of Revenue | CN¥737.63m |
| Gross Profit | CN¥750.25m |
| Other Expenses | CN¥350.90m |
| Earnings | CN¥399.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 50.42% |
| Net Profit Margin | 26.84% |
| Debt/Equity Ratio | 11.6% |
How did 300109 perform over the long term?
See historical performance and comparison